Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR2554 Combinations in Advanced or Metastatic NSCLC
NCT07175220Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zeprumetostat in non-small cell lung cancer (NSCLC), sponsored by Hengrui. Started Oct 2025; status: recruiting.
02
Drugs
zeprumetostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07175220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07175220.